Wedbush Weighs in on Biogen's Q2 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for Biogen in a research report issued to clients and investors on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $4.15 for the quarter, up from their previous estimate of $3.95. Wedbush has a "Neutral" rating and a $121.00 price objective on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's FY2025 earnings at $15.09 EPS, Q2 2026 earnings at $4.08 EPS, Q4 2026 earnings at $3.88 EPS, FY2026 earnings at $15.90 EPS, FY2027 earnings at $17.30 EPS, FY2028 earnings at $20.56 EPS and FY2029 earnings at $21.24 EPS.

A number of other research firms also recently commented on BIIB. Robert W. Baird reduced their target price on Biogen from $300.00 to $255.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and set a $187.00 target price on shares of Biogen in a research note on Thursday, June 26th. Morgan Stanley decreased their target price on Biogen from $157.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Piper Sandler reissued a "neutral" rating and set a $115.00 target price on shares of Biogen in a research note on Thursday, June 12th. Finally, HSBC lowered Biogen from a "buy" rating to a "hold" rating and set a $118.00 target price on the stock. in a research note on Monday, April 28th. Twenty research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Biogen has a consensus rating of "Hold" and a consensus target price of $188.48.

Biogen Trading Down 2.9%

NASDAQ BIIB traded down $3.70 on Thursday, reaching $124.99. 1,524,813 shares of the company were exchanged, compared to its average volume of 1,451,577. The business's fifty day moving average price is $129.18 and its 200 day moving average price is $133.17. The stock has a market capitalization of $18.31 billion, a P/E ratio of 12.34, a price-to-earnings-growth ratio of 1.00 and a beta of 0.14. The company has a current ratio of 1.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.27. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $236.48.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The business had revenue of $2.43 billion during the quarter, compared to analysts' expectations of $2.25 billion. Biogen had a net margin of 15.07% and a return on equity of 14.03%. The firm's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $3.67 earnings per share.

Insiders Place Their Bets

In other Biogen news, insider Rachid Izzar sold 2,223 shares of the firm's stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $135.00, for a total transaction of $300,105.00. Following the completion of the transaction, the insider owned 6,330 shares of the company's stock, valued at approximately $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.18% of the company's stock.

Institutional Investors Weigh In On Biogen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lee Danner & Bass Inc. acquired a new position in shares of Biogen during the fourth quarter worth about $25,000. Opal Wealth Advisors LLC acquired a new position in shares of Biogen during the first quarter worth about $26,000. Vision Financial Markets LLC acquired a new position in shares of Biogen during the first quarter worth about $27,000. Greykasell Wealth Strategies Inc. acquired a new position in shares of Biogen during the first quarter worth about $27,000. Finally, Colonial Trust Co SC lifted its stake in shares of Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.